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PREVIOUS clinical studies of Streptonigrin have been carried out in the United
States of America. Hackethal et al. (1961), reviewing a series of patients with
advanced malignant disease treated by single daily intravenous injections of the
drug, came to the conclusion that although improvement was seen in some cases
ofHodgkin's disease, Streptonigrin was probably oflimited clinical value because
of its severe toxic effect upon bone marrow. Other similar studies by Humphrey
and Blank (1961) and Wilson, Labra and Barrist (1961) while demonstrating that
the drug had some anti-tumour activity, also emphasised its depressant effect on
bone marrow.
Sullivan et al. (1963) suggested that by administering streptonigrin by con-
tinuous intravenous infusion its bone marrow toxicity could be diminished
without any concomitant loss of anti-tumour activity. This was supported by
Harris et al. (1964) who also showed that the drug was effective when administered
orally. In both these more recent trials, significant objective responses in a wide
range of cases ofadvanced malignant disease were reported.
With these facts in mind, we have conducted a clinical trial of Streptonigrin
on a small group (21) of patients with advanced malignant disease. Our dosage
r6gime was based on the report on the use ofthe drug by Harris et al. (1964). The
results recorded are those of the first clinical trial of the drug in the United
Kingdom.
Streptonigrin
Streptonigrin is an antibiotic substance isolated from broth filtrates of
Streptomyces flocculus. Its empirical formula is C25H2208N4 and its structural
formula is:
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It is a dark brown crystalline solid which behaves as a weak acid and is slightly
soluble in water, lower alcohols, ethyl acetate and chloroform.
For parenteral use the drug is supplied in two vials. One vial contains 0'5 mg.
of crystalline Streptonigrin mixed with 100 mg. of mannitol. The second vial
contains 3 ml. of a diluent composed of 10% dimethyl sulfoxide, 10 % ethanol,
2*2 % 0*05 M citric acid and 77*8 % 0-1 M disodium phosphate. Before use,
2-5 ml. of the diluent is added to the vial containing Streptonigrin. Each
millilitre of the resulting solution contains 0-2 mg. of Streptonigrin. An appro-
priate amount ofthe concentrated solution is then withdrawn and transferred to a
larger volume of 5 % glucose in water for intravenous infusion.
Capsules for oral administration of the drug contain 0-2 mg. of Streptonigrin.
Selection ofPatients
The first trial of Streptonigrin in the United Kingdom has been carried out on
a wide range of cases of advanced malignancy, the majority of whom had had
previous treatment. The range of tumour types studied is shown in Table I, the
age range in Table II, and the extent of previous therapy in Table III.
TABLE I.-Histological Diagnosis and Site of Primary Lesion in
Patients with Malignant Disease Treated with Streptonigrin
Histological diagnosis
Hodgkin's disease
Adenocarcinoma
Not determined
Astrocytoma
Ependymoblastoma
Neuroblastoma
Squamous cell carcinoma
Adenocarcinoma
Adenocarcinoma
Not determined
Cystadenocarcinoma
Malignant melanoma
Round cell sarcoma
Squamous cell carcinoma
Adenocarcinoma
Adenocarcinoma
Acute monocytic leukaemia
Site of primary lesion Numbers
3
Breast . 2
Breast . 1
Brain . 2
Brain . 1
Lumbar extradural space . 1
Oesophagus . 1
Gall-bladder . 1
Colon . 1
Lung . 1
Ovary . 1
Skin . 1
Tibia . 1
Cervical lymph nodes . 1
Unknown ? stomach . 1
Unknown ? ovary . 1
- . 1
21
TABLE II.-Age Range ofPatients Treated with Streptonigrin
Age group Individual ages Numbers
0-9 .6 . 1
10-19 . 14,18 . 2
20-29 . 22, 28 . 2
30-39 . 32 . 1
40-49 . 41, 46 . 2
50-59 . 50,51, 57,58 . 4
60-69 . 62, 65, 65, 66, 67, 69 . 6
70-79 . 74, 78 . 2
80-89 . 80 . 1
21
Average Age = 50 years.
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TABLE III.-Extent ofPrevious Therapygiven toPatients treated
withStreptonigrin
Type of treatment Numbers
Surgery + Radiotherapy + Cytotoxic agents . 5
Surgery + Radiotherapy. . . . 2
Radiotherapy + Cytotoxic agents . . 2
Surgery alone. . . . . . 8
Radiotherapy alone . . . . . 2
No previous treatment . . . . . 2
21
Therapeutic Regime
A combination of intravenous and oral routes of administration was used in
the majority of cases (16). In fifteen of these the period of intravenous therapy
was followed immediately, or within a few days, by an oral course of the drug.
In one patient there was an interval of three months between intravenous and
oral treatment. Four patients received the drug only by the intravenous route,
and one patient only by the oral route.
Intravenous Therapy
The drug was administered by continuous intravenous infusion over a period
of four to ten days, the calculated daily dose (7 4ug./kg. to a maximum of 500
micrograms) being mixed with 1 litre of 5 % dextrose in water.
Oral Therapy
The drug was administered in the form of 0-2 mg. capsules. It was planned to
give 04 mg. daily for two weeks followed by 0-2 mg. daily for a further six weeks
but severe toxic symptoms or death of the patient supervened in most instances,
and only one patient completed the full course of oral therapy.
Side Effects
Nearly half (10) of the patients complained of nausea or vomiting. In most
instances these symptoms were satisfactorily controlled with anti-emetic com-
pounds, but in two patients persistent severe vomiting necessitated discontinua-
tion of Streptonigrin. Two patients suffered from troublesome diarrhoea.
Partial loss ofhead hair was noted in three cases.
Evidence of toxicity to the bone marrow was present in more than half the
patients (11) and was the reason for discontinuation of treatment in seven cases.
A combination ofleucopenia (< 4000/cu. mm.) andthrombocytopenia (< 100,000/
cu. mm.) occurred in three patients, leucopenia alone occurred in four patients,
and thrombocytopenia alone in two patients. Lymphopenia (< 1000/cu. mm.)
was noted in two cases.
RESULTS
An analysis of the clinical material used to assess Streptonigrin in this trial,
together with a summary ofthe results oftreatment, is shown in Table IV.
Of the twenty-one patients who were treated, the majority (18) showed no
improvement. Within three months of starting treatment eleven patients had
13
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died of their disease. Four patients died during the course of treatment, but
from causes other than could be ascribed to drug toxicity.
Temporary improvement following treatment was noted in two patients.
One of these was a case of Hodgkin's disease, who showed a definite response
following an intravenous course of Streptonigrin. Subjectively pruritus and
lumbar backache due to vertebral deposits diminished and objectively an enlarged
cervical lymph node became much smaller. The remission lasted two months.
When symptoms recurred, he was given a course of Streptonigrin orally. This
produced a slight subjective response only.
The other case to show temporary improvement was a child with an ependy-
moblastoma ofthe IVth ventricle, who was treated with a course ofStreptonigrin
by mouth. General clinical improvement was noted for two months following
therapy, and she was able to return to school. Her disease, however, recurred
and she died three months after starting treatment.
One patient has shown a prolonged remission. A month before treatment with
Streptonigrin she underwent hysterectomy and bilateral salpingo-oophorectomy
for cystadenocarcinoma of the ovary. At operation it was noted that metastatic
deposits were present throughout the peritoneal cavity. Four months after
treatment she remains well, and there has been no evidence of recurrence of
malignant disease. It is of interest that this patient was the only one in the
trial to complete the full course oftreatment. Shereceived a total dose of 16-9 mg.
(338 ,ug./kg.) of Streptonigrin.
DISCUSSION
Although previous clinical trials suggest that Streptonigrin may have a place
in the treatment of advanced malignant disease, our experience with this drug
has been disappointing. Remission was obtained in only three patients, and in
two ofthese cases the remission lasted less than three months.
The incidence ofdrug toxicity was found to be disturbingly high. As has been
mentioned, the toxic effect on bone marrow was particularly marked and was an
important factor in limiting the therapeutic dose. Marrow depression has
previously been noted to occur commonly twenty to thirty days after the start of
treatment by Wilson, Labra and Barrist (1961) and Sullivan et al. (1963). This
was confirmed in the present study where the mean time to greatest depression of
marrow function from the beginning oftreatment was twenty-six days. Although
no deaths occurred which could be directly attributed to the drug, in two instances
the course of the patient's disease was complicated by toxicity to the marrow.
One patient with severe leucopenia (W.B.C. = 121/cu. mm.) developed broncho-
pneumonia, and another with thrombocytopenia (platelets = 7500/cu. mm.)
required hospital admission for treatment ofpersistent bleeding from an ulcerating
squamous cell carcinoma.
In previous studies by Sullivan et al. (1963) and Harris et al. (1964), Strepto-
nigrin has shown most promise in the treatment oflymphomas, mycosis fungoides,
chronic lymphatic leukaemia, metastatic breast carcinoma and the sarcomas.
The present series includes a relatively small proportion (33 %) of such cases
and this may partly account for the disappointing results obtained. In particular
the drug has previously been found useful in the management of Hodgkin's
disease. In the present trial a short temporary remission was obtained in only
one ofthree cases ofHodgkin's disease treated. It must be emphasised, however,
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that the two cases which showed no response were both far advanced in the course
of their disease, and one of them received a total dose of Streptonigrin which
could be considered to be inadequate (29.7 ,ug./kg.).
Although the results of the present trial are not encouraging, it should be
stressed that all the patients considered by us for treatment with Streptonigrin
had far-advanced malignant disease, which in the majority had proved resistant
to previous therapy. In view of this, further study of the drug should be con-
sidered in relatively early cases of malignant disease, and particularly in the
lymphomas, mycosis fungoides, chronic lymphatic leukaemia, metastatic breast
carcinoma and various types of sarcoma.
SUMMARY
The first trial of Streptonigrin in the United Kingdom is described. Twenty-
one patients with a wide range of advanced malignant disease were treated.
Eighteen patients showed no response to the drug. A temporary remission was
obtained in two cases. One patient has had a prolonged remission. A dis-
turbingly high incidence of side-effects, in particular depression of bone marrow
function, was noted.
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